- Home
- EARN vs ACHV Comparison
EARN vs ACHV Comparison
Compare EARN & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EARN
- ACHV
- Stock Information
- Founded
- EARN 2012
- ACHV N/A
- Country
- EARN United States
- ACHV Canada
- Employees
- EARN N/A
- ACHV N/A
- Industry
- EARN Real Estate Investment Trusts
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EARN Real Estate
- ACHV Health Care
- Exchange
- EARN Nasdaq
- ACHV Nasdaq
- Market Cap
- EARN 177.0M
- ACHV 159.0M
- IPO Year
- EARN 2013
- ACHV N/A
- Fundamental
- Price
- EARN $6.95
- ACHV $4.52
- Analyst Decision
- EARN Hold
- ACHV Strong Buy
- Analyst Count
- EARN 2
- ACHV 3
- Target Price
- EARN $6.00
- ACHV $14.00
- AVG Volume (30 Days)
- EARN 371.1K
- ACHV 85.7K
- Earning Date
- EARN 08-12-2024
- ACHV 11-07-2024
- Dividend Yield
- EARN 13.86%
- ACHV N/A
- EPS Growth
- EARN 102.38
- ACHV N/A
- EPS
- EARN 0.23
- ACHV N/A
- Revenue
- EARN $18,419,000.00
- ACHV N/A
- Revenue This Year
- EARN N/A
- ACHV N/A
- Revenue Next Year
- EARN $51.24
- ACHV N/A
- P/E Ratio
- EARN $29.84
- ACHV N/A
- Revenue Growth
- EARN N/A
- ACHV N/A
- 52 Week Low
- EARN $5.09
- ACHV $3.03
- 52 Week High
- EARN $7.26
- ACHV $5.98
- Technical
- Relative Strength Index (RSI)
- EARN 49.75
- ACHV 50.71
- Support Level
- EARN $6.85
- ACHV $4.23
- Resistance Level
- EARN $6.95
- ACHV $4.33
- Average True Range (ATR)
- EARN 0.09
- ACHV 0.15
- MACD
- EARN 0.00
- ACHV 0.02
- Stochastic Oscillator
- EARN 46.87
- ACHV 53.13
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.